Next report date
Report period
Q1 2024
EPS estimate
−4.86MXN
Revenue estimate
—
−9.71MXN
−602.43 MMXN
43.34 M
About ProKidney Corp.
Sector
Industry
CEO
Bruce Culleton
Website
Headquarters
Winston-Salem
Employees (FY)
163
Founded
2015
FIGI
BBG014RL5BZ6
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PROK/N is 44.55 MXN — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange PROKIDNEY CORP stocks are traded under the ticker PROK/N.
PROKIDNEY CORP is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
PROK/N stock is 0% volatile and has beta coefficient of 1.62. Check out the list of the most volatile stocks — is PROKIDNEY CORP there?
PROK/N earnings for the last quarter are −3.14 MXN per share, whereas the estimation was −2.75 MXN resulting in a −14.02% surprise. The estimated earnings for the next quarter are −2.43 MXN per share. See more details about PROKIDNEY CORP earnings.
Yes, you can track PROKIDNEY CORP financials in yearly and quarterly reports right on TradingView.
PROK/N stock has fallen by 12.90% compared to the previous week, the month change is a 71.35% rise, over the last year PROKIDNEY CORP has showed a 77.39% decrease.
PROK/N net income for the last quarter is −96.83 M MXN, while the quarter before that showed −191.46 M MXN of net income which accounts for 49.42% change. Track more PROKIDNEY CORP financial stats to get the full picture.
Today PROKIDNEY CORP has the market capitalization of 2.41 B, it has increased by 0.40% over the last week.
No, PROK/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PROK/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROKIDNEY CORP stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 163.00 employees. See our rating of the largest employees — is PROKIDNEY CORP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROKIDNEY CORP technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROKIDNEY CORP stock shows the buy signal. See more of PROKIDNEY CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PROKIDNEY CORP future price: according to them, PROK/N price has a max estimate of 102.50 MXN and a min estimate of 34.17 MXN. Read a more detailed PROKIDNEY CORP forecast: see what analysts think of PROKIDNEY CORP and suggest that you do with its stocks.